Product Name :
(S)-Thalidomide
Description:
(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) .
CAS:
841-67-8
Molecular Weight:
258.23
Formula:
C13H10N2O4
Chemical Name:
(S)-2-(2, 6-dioxopiperidin-3-yl)isoindoline-1, 3-dione
Smiles :
O=C1CC[C@@H](C(=O)N1)N1C(=O)C2C=CC=CC=2C1=O
InChiKey:
UEJJHQNACJXSKW-VIFPVBQESA-N
InChi :
InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) .|Product information|CAS Number: 841-67-8|Molecular Weight: 258.23|Formula: C13H10N2O4|Chemical Name: (S)-2-(2, 6-dioxopiperidin-3-yl)isoindoline-1, 3-dione|Smiles: O=C1CC[C@@H](C(=O)N1)N1C(=O)C2C=CC=CC=2C1=O|InChiKey: UEJJHQNACJXSKW-VIFPVBQESA-N|InChi: InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Bepridil} site|{Bepridil} Neuronal Signaling|{Bepridil} Biological Activity|{Bepridil} In Vitro|{Bepridil} supplier|{Bepridil} Autophagy} |Shelf Life: ≥12 months if stored properly.{{Venetoclax} web|{Venetoclax} Bcl-2 Family|{Venetoclax} Purity & Documentation|{Venetoclax} References|{Venetoclax} supplier|{Venetoclax} Epigenetic Reader Domain} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:24220671 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|(S)-Thalidomide treatment results in a reduction in cell viability in U266 cells with an IC50 of 362 μM. (S)-Thalidomide treatment increased apoptosis in a dose-dependent manner in U266 cells. There are changes in the expression profile of genes involved in angiogenesis and apoptosis, but the changes are most dramatic in the apoptotic genes. In particular, the expression of I-κB kinase is decreased by two-fold, which is associated with a four-fold decrease in NF-κB expression. (S)-Thalidomide increases the Bax:Bcl-2 ratio, also increases I-kB protein levels, and decreases NF-kB activity. A dramatic decrease in Bcl-2 expression with (S)-Thalidomide suggests a possible enhancement of cytotoxic effect if combined with other cytotoxic agents.|In Vivo:|Thalidomide does cause limb reduction defects in chick embryos as long as the embryos are directly exposed to the drug. The most useful techniques are implanting Thalidomide-soaked beads into the embryo immediately adjacent to the limb territory or soaking presumptive chick limb territories in Thalidomide and then grafting the explants to a host embryo celom. Thalidomide affects the chick limb grafted to a host embryo in a dose response fashion. Furthermore, (S)-Thalidomide is more teratogenic than (R)-Thalidomide.|Products are for research use only. Not for human use.|